MY112949A - Benzo-thiaphene estrogen agonists to treat prostatic hyperplasia - Google Patents

Benzo-thiaphene estrogen agonists to treat prostatic hyperplasia

Info

Publication number
MY112949A
MY112949A MYPI95003850A MYPI19953850A MY112949A MY 112949 A MY112949 A MY 112949A MY PI95003850 A MYPI95003850 A MY PI95003850A MY PI19953850 A MYPI19953850 A MY PI19953850A MY 112949 A MY112949 A MY 112949A
Authority
MY
Malaysia
Prior art keywords
thiaphene
benzo
estrogen agonists
prostatic hyperplasia
treat prostatic
Prior art date
Application number
MYPI95003850A
Inventor
D Thompson David
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MY112949A publication Critical patent/MY112949A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

BENZOTHIOPHENES AND RELATED COMPOUNDS OF THE FORMULA ARE ESTROGEN AGONISTS WHICH ARE USEFUL FOR TREATING PROSTATIC AND DISEASES, OBESITY AND BONE LOSS IN MALE ANIMALS.
MYPI95003850A 1994-12-14 1995-12-13 Benzo-thiaphene estrogen agonists to treat prostatic hyperplasia MY112949A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/356,011 US5589482A (en) 1994-12-14 1994-12-14 Benzo-thiophene estrogen agonists to treat prostatic hyperplasia

Publications (1)

Publication Number Publication Date
MY112949A true MY112949A (en) 2001-10-31

Family

ID=23399729

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI95003850A MY112949A (en) 1994-12-14 1995-12-13 Benzo-thiaphene estrogen agonists to treat prostatic hyperplasia

Country Status (12)

Country Link
US (1) US5589482A (en)
EP (1) EP0716855A2 (en)
JP (1) JPH08231540A (en)
KR (1) KR100190724B1 (en)
CN (1) CN1130063A (en)
AU (1) AU696573B2 (en)
CA (1) CA2165012C (en)
IL (1) IL116283A (en)
MX (1) MX9505249A (en)
MY (1) MY112949A (en)
NZ (1) NZ280667A (en)
ZA (1) ZA9510592B (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0801066A1 (en) * 1996-03-12 1997-10-15 Eli Lilly And Company Heterocyclic substituted benzothiophenes and pharmaceutical compositions
CA2218756A1 (en) * 1996-10-25 1998-04-25 Kristin Sue Marron Substituted benzo¢b!thiophene compounds having activity as selective estrogen receptor modulators
US6271227B1 (en) 1997-04-30 2001-08-07 Eli Lilly And Company Antithrombotic Agents
GB2324726A (en) * 1997-05-01 1998-11-04 Merck & Co Inc Combination Therapy for the Treatment of Osteoporosis
CA2304138A1 (en) * 1997-09-23 1999-04-01 Eli Lilly And Company Benzothiophenes
BR9812944A (en) 1997-10-20 2000-08-08 Hoffmann La Roche Bicyclic kinase inhibitors
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
CN1615873A (en) 1999-12-24 2005-05-18 阿文蒂斯药物有限公司 Azaindoles compound
DE60124616T2 (en) * 2000-05-08 2007-09-13 Pfizer Products Inc., Groton Enzymatic cleavage of selective modulators of the estrogen receptor
CA2412462A1 (en) 2000-06-14 2001-12-20 Warner-Lambert Company 6,5-fused bicyclic heterocycles
DE60108710T2 (en) * 2000-11-30 2006-05-04 Pfizer Products Inc., Groton Estrogen agonist antagonist and testosterone-containing composition for the treatment of decreasing testosterone levels
AU781168B2 (en) * 2001-01-26 2005-05-12 Pfizer Products Inc. Method of treating certain cancers using an estrogen agonist/antagonist
GB0112834D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
AU2003246972A1 (en) 2002-08-06 2004-02-23 Astrazeneca Ab Condensed pyridines and pyrimidines with tie2 (tek) activity
US20050261347A1 (en) * 2003-10-24 2005-11-24 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
US7435837B2 (en) * 2003-10-24 2008-10-14 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
MXPA06014471A (en) 2004-06-09 2007-03-21 Glaxo Group Ltd Pyrrolopyridine derivatives.
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
WO2006019831A1 (en) 2004-07-14 2006-02-23 Ptc Therapeutics, Inc. Methods for treating hepatitis c
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
JP2008507518A (en) 2004-07-22 2008-03-13 ピーティーシー セラピューティクス，インコーポレーテッド Thienopyridine for treating hepatitis C
KR101319675B1 (en) * 2008-09-29 2013-10-22 일라이 릴리 앤드 캄파니 Selective estrogen repector modulator for the treatment of osteoarthritis
EP2503188B1 (en) * 2011-03-25 2015-01-21 NAF Neunkirchener Achsenfabrik AG Switching cylinder for a drive device, in particular for a self-propelled work machine, drive device, work machine and method for operating a work machine
BR112015018882B1 (en) 2013-02-19 2021-09-14 Novartis Ag BENZOTHOPHENE DERIVATIVES AND COMPOSITIONS THEREOF AS SELECTIVE ESTOGEN RECEPTOR DEGRADATORS
JP6549735B2 (en) 2015-06-09 2019-07-24 アッヴィ・インコーポレイテッド Nuclear receptor modulator
KR102542698B1 (en) * 2022-04-05 2023-06-14 주식회사 베노바이오 Novel benzothiophene derivatives and use as BET inhibitors

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
EP0062503A1 (en) * 1981-04-03 1982-10-13 Eli Lilly And Company Benzothiophene compounds and process for preparing them
US4358593A (en) * 1981-04-03 1982-11-09 Eli Lilly And Company Process for preparing 3-(4-aminoethoxybenzoyl)benzo[b]thiophenes
IL65378A (en) * 1981-04-03 1986-02-28 Lilly Co Eli Process for preparing 3-(4-aminoethoxybenzoyl)benzo-(b)thiophenes
GB8311678D0 (en) * 1983-04-28 1983-06-02 Ici Plc Phenol derivatives
US4859585A (en) * 1986-04-17 1989-08-22 Trustees Of Tufts College In-vitro methods for identifying compositions which are agonists and antagonists of estrogens
US4970237A (en) * 1987-03-20 1990-11-13 Yale University Use of clomiphene to increase bone mass in premenopausal women
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
DE4117512A1 (en) * 1991-05-25 1992-11-26 Schering Ag 2-PHENYLBENZO (B) FURANES AND THIOPHENES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM
US5147880A (en) * 1991-07-22 1992-09-15 Eli Lilly And Company Benzo[a]fluorene compounds
JP3157882B2 (en) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 New benzothiophene derivatives
US5196435A (en) * 1991-11-21 1993-03-23 Eli Lilly And Company Melatonin derivatives and combinations with antiestrogen compounds for treating mammalian breast carcinoma
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
US6756388B1 (en) * 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
US8135386B2 (en) * 2008-07-09 2012-03-13 Telefoanktebolaget L M Ericsson (Publ) Method and apparatus for instance identifier based on a unique device identifier

Also Published As

Publication number Publication date
EP0716855A3 (en) 1996-07-10
AU4041295A (en) 1996-06-20
US5589482A (en) 1996-12-31
AU696573B2 (en) 1998-09-10
CA2165012A1 (en) 1996-06-15
IL116283A (en) 2002-02-10
CA2165012C (en) 1999-03-16
EP0716855A2 (en) 1996-06-19
CN1130063A (en) 1996-09-04
KR100190724B1 (en) 1999-06-01
IL116283A0 (en) 1996-03-31
MX9505249A (en) 1997-01-31
KR960021020A (en) 1996-07-18
ZA9510592B (en) 1997-06-13
NZ280667A (en) 2000-08-25
JPH08231540A (en) 1996-09-10

Similar Documents

Publication Publication Date Title
MY112949A (en) Benzo-thiaphene estrogen agonists to treat prostatic hyperplasia
NZ285159A (en) Treatment of benign prostatic hyperplasia, endometriosis, prostatic carcinoma and obesity by administration of droloxifene
MY121548A (en) Compounds and methods for the treatment of cancer
DE60032783D1 (en) Thrombopoietinmimetika
ATE208210T1 (en) COMBINATION OF PROTEIN TYROSINE KINASE INHIBITORS AND CHEMICAL CASTRATION FOR THE TREATMENT OF PROSTATE CANCER
PL316651A1 (en) Gel for treating dermatoses and skin disinfecting
MXPA01013395A (en) TREATING PROSTATE CANCER WITH ANTI-ErbB2 ANTIBODIES.
IL189132A0 (en) Pharmaceutical compositions for the treatment of prostate hypertrophy and prostate cancer
HK1029922A1 (en) Angiostatic agents and compositions for treating glc1a glaucoma
EP1213965A4 (en) Thrombopoietin mimetics
EP1009755A4 (en) Steroid sulfatase inhibitors and methods for making and using the same
ZA952763B (en) Use of alpha-1C specific compounds to treat benign prostatic hyperplasia
ZA200003768B (en) Methods and compositions for treating diseases and conditions of the eye.
PL318298A1 (en) Thiopyridil compounds for fighting against heliobacter
RS92304A (en) Pharmaceutical combination for the treatment of benign prostatic hyperplasia or for long-term preservation of acute urinary retention
NO984075L (en) Combination of dehydroepiandrosterone and aromatase inhibitors and use of this combination for the manufacture of a medicament for the treatment of a relative and absolute androgen deficiency in men
IL124650A0 (en) Methods and therapeutic compositions for treating cancer
HK1029944A1 (en) Treatment of follicular lymphomas using inhibitors of the lymphotoxin (lt) pathway
MXPA02001204A (en) Calcilytic compounds.
MX9700624A (en) Imidazopyridine-azolidinones.
ATE250580T1 (en) SUBSTITUTED PYRIDINO-ARYLPIPERAZINE FOR THE TREATMENT OF BENIGGER PROSTATE HYPERPLASIA
MXPA01007952A (en) L-arginine based formulations for treating diseases and methods of using same.
NO975838L (en) Melatonin agonists for the treatment of benign prostatic hyperplasia
UA32153A (en) Technique for generating graft for pull-through proctectomy
MX9710075A (en) Melatonin agonists for treating benign prostatic hyperplasia.